WOBURN, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (YTEN), a Company developing new technologies to create step-change improvements in crop yield that enhance global food security, today named Sherri M. Brown, Ph.D., as a special commercial and technical advisor to the Company, effective immediately. Dr. Brown is currently managing director of The Yield Lab, a global agrifood tech accelerator based in St. Louis. She previously served in a number of leadership positions involving the development and global commercialization of new biotechnology traits for canola, soybean and corn at Monsanto Company for 28 years.
“We are delighted to welcome Dr. Brown, an agricultural industry leader of tremendous caliber, to a crucial advisory role with Yield10. She possesses a wealth of experience leading teams that have successfully developed and commercialized innovative biotechnology traits globally in canola, soybean and corn,” said Oliver Peoples, Ph.D., president and chief executive officer of Yield10. “Her extensive background in plant science, the assessment of yield traits in the field, global experience, and knowledge of the commercial landscape will make her an invaluable resource for our team during this important period of our growth.”
“The Yield10 team brings a differentiated approach and new insights to the identification of novel yield traits for commercial food and feed crops, which has led to the discovery and evaluation of a remarkable pipeline of yield traits,” said Dr. Brown. “The outcomes they have reported to date have been impressive, and I look forward to working with their team to contribute to the Company's success.”
Dr. Brown joined The Yield Lab as Managing Director in 2017. From 1989 to 2017, she served in a number of leadership positions at Monsanto, most involving the development and global commercialization of new traits for corn and oilseed crops including soybean and canola. Dr. Brown most recently served as Vice President, Science Strategy at Monsanto from 2014 to 2017 and as a member of the Monsanto Leadership Council. Prior to that, she was Vice President, Global Commercial Technology/Product Development from 2008 to 2014 where she was responsible for evaluating and launching the seed and trait pipeline, including eight new biotech traits. In addition, she was Vice President, Technology, Global Corn Business (1999-2004) and Vice President, Technology, Oilseeds Business team (1998-1999). Dr. Brown earned a Ph.D. at Indiana University, Bloomington, IN with a major in Genetics/Molecular, Cellular and Developmental Biology. She earned a B.S. at Hope College, Holland, MI with a double major in Biology and Chemistry.
About Yield10 Bioscience
Yield10 Bioscience, Inc. is focused on developing new technologies to achieve step-change improvements in crop yield to enhance global food security. Yield10 has an extensive track record of innovation based around optimizing the flow of carbon in living systems.Yield10 is leveraging its technology platforms and unique knowledge base to design precise alterations to gene activity and the flow of carbon in plants to produce higher yields with lower inputs of land, water or fertilizer. Yield10 is advancing several yield traits it has developed in crops such as Camelina, canola, soybean and rice. Yield10 is headquartered in Woburn, MA and has an Oilseeds Center of Excellence in Saskatoon, Canada.
For more information about the company, please visit www.yield10bio.com.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical, including, without limitation, those relating to the Company’s growth and the potential for successful development and commercialization of new yield traits, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Yield10 Bioscience's filings with the Securities and Exchange Commission. Yield10 assumes no obligation to update any forward-looking information contained in this press release or with respect to the matters described herein.